IBI362 Phase 1/2 Study Evaluates Safety and PK/PD in Overweight and Obesity

Globally, obesity and overweight conditions represent significant public health challenges, contributing to an increased risk of numerous chronic diseases such as type 2 diabetes, cardiovascular disease, and certain cancers. The urgent need for effective and safe pharmacological interventions to manage weight is paramount. This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI362 in affected individuals.

This completed Phase 1/2 study successfully enrolled its target of 60 participants, investigating IBI362 in individuals with overweight or obesity. The primary objectives of evaluating IBI362's safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) were thoroughly investigated across multiple ascending doses. While the trial's completion is noted, the provided research record does not detail specific findings regarding adverse events, precise PK parameters, or quantitative PD outcomes such as weight loss percentages or metabolic improvements. The study confirmed the feasibility of administering IBI362 in overweight or obese subjects, successfully completing its initial human evaluation phase. Without specific data, quantitative comparisons between IBI362 and placebo regarding efficacy or specific safety metrics cannot be made from this summary.